Wall Street analysts expect OncoCyte Corporation (NASDAQ:OCX) to announce ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for OncoCyte’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.10). OncoCyte reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.7%. The company is expected to announce its next quarterly earnings report after the market closes on Wednesday, August 14th.
According to Zacks, analysts expect that OncoCyte will report full-year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.41) to ($0.34). For the next financial year, analysts forecast that the business will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.53) to ($0.38). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow OncoCyte.
OncoCyte (NASDAQ:OCX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.02.
Shares of OCX traded up $0.03 during mid-day trading on Friday, hitting $1.67. 140,976 shares of the company’s stock were exchanged, compared to its average volume of 738,523. OncoCyte has a fifty-two week low of $1.16 and a fifty-two week high of $6.92. The company has a 50 day simple moving average of $2.51.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.